Otonomy 2018 First Quarter Financial Results

Otonomy posted their 1st quarter financial results today.
I think most of the stuff in there is already known, however, it gives a nice short summary about their drug pipeline.

http://investors.otonomy.com/news-r...orts-first-quarter-2018-financial-results-and

Also, they actually started to earn (a little) money:

 

I also like their logo.

http://www.otonomy.com/pipeline/product-candidates/

 

Imma sit here and watch it move

 

Their products look horrible. The tinnitus drug is in a class of drugs called a dissociative. Look that up. I think I'd rather have tinnitus then take that crap. This just reinforces my belief that big pharma is a big pile of poop.

 

https://globenewswire.com/news-rele...O-413-Presentation-Selected-as-Hot-Topic.html

 

They still haven’t said if OTO-313 is for chronic or acute tinnitus. Anybody know what it’s aimed for?

How about Auris Medical's AM-102?

 

At least they are combining the phases with OTO-413

 

"...We are also excited to advance OTO-413 into clinical trials next year for patients with speech-in-noise hearing difficulties, and expect that this will be the first such trial evaluating a potential treatment for cochlear synaptopathy.”
I think this could still mean they're only evaluating for safety. :/

 

Of course. But it is a “potential treatment”. That means that they want it to be a treatment. If there are positive results and they feel like they are viable then it’s good news.

 

Gotcha. I was commenting on the phase combination/separation thing.

 

@Manny
Oh, I see what you’re saying. I’m not terribly worried tho. Otonomy sucks so much that they will take the wins wherever they can. At this point, they can’t afford to just conduct random research assignments without a means to an end (or drug). Out of all of their hearing loss trials, I think this is the best one. I just want to find a patent or something.